Analyzing Rockwell Medical (RMTI) & its Rivals
Rockwell Medical (NASDAQ: RMTI) is one of 19 publicly-traded companies in the “Specialty & Advanced Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Rockwell Medical to similar companies based off the strength of its profitability, earnings, analyst recommendations, dividends, valuation, institutional ownership and risk.
This is a breakdown of recent recommendations and price targets for Rockwell Medical and its competitors, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Rockwell Medical Competitors||97||362||955||28||2.63|
Rockwell Medical currently has a consensus price target of $9.33, indicating a potential upside of 48.38%. All “Specialty & Advanced Pharmaceuticals” companies have a potential upside of 25.05%. Given Rockwell Medical’s stronger consensus rating and higher probable upside, research analysts clearly believe Rockwell Medical is more favorable than its competitors.
This table compares Rockwell Medical and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Rockwell Medical Competitors||-538.85%||-41.85%||-24.81%|
Institutional & Insider Ownership
21.4% of Rockwell Medical shares are held by institutional investors. Comparatively, 66.5% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by institutional investors. 15.9% of Rockwell Medical shares are held by insiders. Comparatively, 10.0% of shares of all “Specialty & Advanced Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Valuation and Earnings
This table compares Rockwell Medical and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||EBITDA||Price/Earnings Ratio|
|Rockwell Medical||$54.04 million||-$21.07 million||-14.98|
|Rockwell Medical Competitors||$2.40 billion||$906.33 million||4.02|
Rockwell Medical’s competitors have higher revenue and earnings than Rockwell Medical. Rockwell Medical is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently the more affordable than other companies in its industry.
Volatility and Risk
Rockwell Medical has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500. Comparatively, Rockwell Medical’s competitors have a beta of 0.81, meaning that their average share price is 19% less volatile than the S&P 500.
About Rockwell Medical
Rockwell Medical, Inc. (Rockwell) is a biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis. The Company operates through the hemodialysis market segment, which involves the manufacture, sale and distribution of hemodialysis products to hemodialysis clinics, including pharmaceutical, dialysis concentrates, dialysis kits and other ancillary products used in the dialysis process. The Company’s drug products include Triferic (ferric pyrophosphate citrate) and Calcitriol (Active Vitamin D) Injection. Triferic is an iron compound that is delivered to hemodialysis patients through dialysate, replacing the iron loss that occurs during their dialysis treatment. Calcitriol (active vitamin D) injection is indicated for treatment of secondary hyperparathyroidism in dialysis patients.
Receive News & Ratings for Rockwell Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rockwell Medical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.